Lyell Immunopharma (LYEL)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Cell Therapysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 61/100 (HIGH), 13.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 12.16% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
- Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
- Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet
- Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
- Is Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans?
- Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 Study
- Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Top advances of the year in autologous cellular therapy in melanoma and solid tumors. — Cancer 2026 Sep 15 PMID 42734903
- Statistical analysis plan considerations for autologous cell and cell-based gene therapy clinical trials. — J Biopharm Stat 2026 Jul 16 PMID 42460470
- Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study. — Clin Breast Cancer 2026 Aug PMID 42431148
- Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy. — Circ Heart Fail 2026 Aug PMID 42389794
- Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer. — Gynecol Oncol 2026 Aug PMID 42385609
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Lyell Immunopharma.
Full LYEL Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.